Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H24FN3O2 |
Molecular Weight | 393.454 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CCN2CCC(CC2)C(=O)C3=CC=C(F)C=C3)C(=O)N4C=CC=CC4=N1
InChI
InChIKey=HXCNRYXBZNHDNE-UHFFFAOYSA-N
InChI=1S/C23H24FN3O2/c1-16-20(23(29)27-12-3-2-4-21(27)25-16)11-15-26-13-9-18(10-14-26)22(28)17-5-7-19(24)8-6-17/h2-8,12,18H,9-11,13-15H2,1H3
Molecular Formula | C23H24FN3O2 |
Molecular Weight | 393.454 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pirenperone, a quinazoline derivative, is a selective antagonist at serotonin receptor 2A binding sites. The liposoluble compound pirenperone has been studied in a variety of behavioral tests including the sensitive d-lysergic acid diethylamide (LSD) cue discrimination assay, in which it served as a potent LSD-antagonist. Pirenperone also proved to be an effective antagonist of serotonin-mediated behavioral responses including the head twitch response thought to be mediated by serotonin receptors.
CNS Activity
Originator
Sources: https://www.google.com/patents/US4342870
Curator's Comment: # Janssen Pharmaceutica N.V.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8632342 |
61.0 nM [Ki] | ||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8632342 |
1.08 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8632342 |
77.0 nM [Ki] | ||
Target ID: CHEMBL3155 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9298538 |
8.19 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist. | 1985 Mar-Apr |
|
Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors. | 1997 Feb |
|
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). | 1997 Sep |
|
The role of serotonin(2) receptors in mediating cocaine-induced convulsions. | 2000 Apr |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2811853
The steric chemical information was used to predict the activity of serotonergic compounds that had never been analyzed at serotonin 3 (5-HT3) receptor binding sites. Two serotonergic drugs that meet all steric criteria were found to be active at the 5-HT3 receptor binding site (i.e., pizotifen, Ki = 42 +/- 10 nM, and clozapine, Ki = 52 +/- 8 nM). By contrast, two serotonergic agents that do not meet the criteria were found to be inactive at the 5-HT3 receptor binding site (i.e., ipsapirone and pirenperone, Ki values greater than 1000 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:35 GMT 2023
by
admin
on
Fri Dec 15 16:25:35 GMT 2023
|
Record UNII |
Y9FMC4513X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9045182
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
C034177
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
760095
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
Y9FMC4513X
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
5065
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
Pirenperone
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL18331
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
278-213-5
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
SUB09903MIG
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
4847
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
75444-65-4
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
C66417
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY | |||
|
100000081643
Created by
admin on Fri Dec 15 16:25:35 GMT 2023 , Edited by admin on Fri Dec 15 16:25:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |